P300 as a clinical assay: rationale, evaluation, and findings.
Use of the P300 event-related brain potential (ERP) as a clinical assay is reviewed and assessed by comparing its distribution qualities with normative biomedical testing data from published studies. The coefficient of variation statistic was calculated for P300 data and a variety of clinical testing data. P300 amplitude and latency variability was found to be highly comparable and sometimes superior to routinely employed biomedical assays. These results are discussed in terms of how to control inter-group ERP variability and the application of normative P300 data in clinical settings.
Polich
J
J
Department of Neuropharmacology, TPC-10, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. polich@scripps.edu
Herbst
K L
KL
D000161:Acoustic Stimulation; D000544:Alzheimer Disease / Q000175:diagnosis; D000818:Animals; D015415:Biomarkers; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D018913:Event-Related Potentials, P300 / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D009422:Nervous System Diseases / Q000175:diagnosis*; D010775:Photic Stimulation; D011603:Psychophysiology
D015415:Biomarkers